Prevalence and Molecular Identification of Human Schistosomiasis

Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07482215

Enrollment

359

Registered

2026-03-19

Start date

2026-05-01

Completion date

2027-12-01

Last updated

2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosomiasis

Brief summary

Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma

Detailed description

Schistosomiasis has been diagnosed in Egypt since pharaonic times (3200 B.C.) by recovering Schistosome eggs and antigens in ancient mummies.In Egypt, Schistosoma mansoni and Schistosoma haematobium have historically been highly endemic, with widespread distribution along the Nile Delta and Valley.(4) Schistosoma haematobium is responsible for urogenital schistosomiasis, with hematuria as its primary manifestation, while Schistosoma mansoni, the prevalent species in Egypt, is causing intestinal schistosomiasis with liver-related sequelae

Interventions

DIAGNOSTIC_TESTMolecular phylogenetic and haplotype analysis

DNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period. * Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination. * Individuals (or guardians, in case of minors) who provide written informed consent. * Patients willing to provide the required biological samples (urine and/or stool).

Exclusion criteria

* Patients Received praziquantel within the last 3 months before sample collection * Patients with incomplete clinical or epidemiological data. * Patients refusing participation or sample collection. * Improperly collected, contaminated, or insufficient samples. * Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure). * children with congenital urinary or intestinal anomalies.

Design outcomes

Primary

Measure	Time frame	Description
prevalence of human schistosomiasis in the study participants	24 hours	using conventional microscopic examination

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026